StockData
Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc. (CRVS) company profile

CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$10.17−0.43 (-4.06%)

Close on Nov 17, 2026Market cap $855.51MP/E –Yield –

About Corvus Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biopharmaceutical enterprise focused on discovering and developing targeted therapies for immune-mediated diseases, inflammatory conditions, and cancers. Its research targets proteins critical to immune cell differentiation and function. The pipeline features soquelitinib, an oral covalent ITK inhibitor being evaluated in clinical studies for peripheral T-cell lymphomas and atopic dermatitis. Additional clinical-stage assets include ciforadenant, an adenosine A2A receptor antagonist under investigation for metastatic renal cell carcinoma, and mupadolimab, a B-cell-activating monoclonal antibody directed against CD73. Because the company does not operate commercial products, its programs address patient populations in specialized clinical trials.

The company operates without internal manufacturing facilities, relying entirely on third-party contract manufacturers to produce, fill, label, package, and distribute its investigational therapies. Its operations and intellectual property span international jurisdictions, maintaining patent protections and applications across the United States, Europe, Canada, Japan, South Korea, Australia, and China. The provided text does not disclose the location of the company's corporate headquarters.

Summary of the business section of Corvus Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Corvus Pharmaceuticals, Inc.
Headquarters
South San Francisco, CA
Address
901 Gateway Blvd, Third Floor 94080
Phone
(650) 900-4520
Employees
37, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopersLLP, San Jose, California

Stock & identifiers

Ticker
CRVS
Exchange
Nasdaq
IPO date
Mar 24, 2016
Shares outstanding
84M, Aug 6, 2026
Public float
$251.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1626971
CUSIP
221015100
ISIN
US2210151005
FIGI
BBG009F0TGH8
Share class FIGI
BBG009F0TGJ6
LEI
549300I3AVJ8F75NCX65
EIN
46-4670809

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Richard A. Miller MdPresident and CEO, Director2,331,742
Jeffrey ArcaraChief Business Officer4,500
Leiv LeaChief Financial Officer282,444
William Benton JonesSee Remarks173,130
den Broek Richard vanDirector160,000
David Scott MooreDirector21,700
Linda GraisDirector10,000
Peter A. ThompsonDirector8,729,091
Ian T. ClarkDirector–
Andrew C. ChanDirector–
Capital GP V. LLC OrbiMedDirector6,943,654
Advisors Llc OrbimedDirector8,341,338
Scott W. MorrisonDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$7.03M$7.33M$3.18M$906–
FY2024$3.07M$7.47M$1.59M$629–
FY2023$1.32M$2.57M$638.51K$207–
FY2022$524.24K-$326.17K$476.70K$35–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsOtherTotalvs. prior year
Richard A. Miller
President and Chief Executive Officer
$36.57K$6.99M$6.00K$7.03M+129%
Leiv Lea
Chief Financial Officer
$405.95K$2.80M$6.00K$3.21M+99%
William B. Jones
Senior Vice President, Pharmaceutical Development
$360.12K$2.80M$6.00K$3.16M+101%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 24, 2016
Offer price
$15.00
Securities offered
4,700,000
Gross proceeds
$70.50M
Exchange
Nasdaq
First trading day
Mar 23, 2016
First-day close
$14.25-5.0%
Lock-up ends (est.)
Sep 19, 2016

“The initial public offering price of our common stock is $15.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 37 total employees, all of whom were full-time and 29 of whom were primarily engaged in research and development activities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?